schliessen

Filtern

 

Bibliotheken

A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models

Rapamycin analogs, temsirolimus and everolimus, are approved for the treatment of advance renal cell carcinoma (RCC). Currently approved agents inhibit mechanistic target of rapamycin (mTOR) complex 1 (mTORC1). However, the mTOR kinase exists...

Journal Title: PLoS ONE 01 January 2013, Vol.8(1), p.e54918
Main Author: Hao Zhang
Other Authors: Dror Berel , Yanping Wang , Ping Li , Neil A Bhowmick , Robert A Figlin , Hyung L Kim
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: E-ISSN: 1932-6203 ; DOI: 10.1371/journal.pone.0054918
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: doaj_soai_doaj_org_article_0be335298182489f86107f3164770aba
title: A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models
format: Article
creator:
  • Hao Zhang
  • Dror Berel
  • Yanping Wang
  • Ping Li
  • Neil A Bhowmick
  • Robert A Figlin
  • Hyung L Kim
subjects:
  • Sciences (General)
ispartof: PLoS ONE, 01 January 2013, Vol.8(1), p.e54918
description: Rapamycin analogs, temsirolimus and everolimus, are approved for the treatment of advance renal cell carcinoma (RCC). Currently approved agents inhibit mechanistic target of rapamycin (mTOR) complex 1 (mTORC1). However, the mTOR kinase exists...
language: eng
source:
identifier: E-ISSN: 1932-6203 ; DOI: 10.1371/journal.pone.0054918
fulltext: fulltext_linktorsrc
issn:
  • 1932-6203
  • 19326203
url: Link


@attributes
ID1452277148
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordidoai_doaj_org_article_0be335298182489f86107f3164770aba
sourceiddoaj_s
recordidTN_doaj_soai_doaj_org_article_0be335298182489f86107f3164770aba
sourcesystemPC
dbidDOA
pqid1282042363
galeid478167076
display
typearticle
titleA comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models
creatorHao Zhang ; Dror Berel ; Yanping Wang ; Ping Li ; Neil A Bhowmick ; Robert A Figlin ; Hyung L Kim
ispartofPLoS ONE, 01 January 2013, Vol.8(1), p.e54918
identifierE-ISSN: 1932-6203 ; DOI: 10.1371/journal.pone.0054918
subjectSciences (General)
descriptionRapamycin analogs, temsirolimus and everolimus, are approved for the treatment of advance renal cell carcinoma (RCC). Currently approved agents inhibit mechanistic target of rapamycin (mTOR) complex 1 (mTORC1). However, the mTOR kinase exists...
languageeng
oafree_for_read
source
version8
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
linktorsrc$$Uhttps://doaj.org/article/0be335298182489f86107f3164770aba$$EView_full_text_in_DOAJ
search
creatorcontrib
0Hao Zhang
1Dror Berel
2Yanping Wang
3Ping Li
4Neil A Bhowmick
5Robert A Figlin
6Hyung L Kim
titleA comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models
description

Rapamycin analogs, temsirolimus and everolimus, are approved for the treatment of advance renal cell carcinoma (RCC). Currently approved agents inhibit mechanistic target of rapamycin (mTOR) complex 1 (mTORC1). However, the mTOR kinase exists...

subjectSciences (General)
general
0English
1Public Library of Science (PLoS)
210.1371/journal.pone.0054918
3Directory of Open Access Journals (DOAJ)
sourceiddoaj_s
recordiddoaj_soai_doaj_org_article_0be335298182489f86107f3164770aba
issn
01932-6203
119326203
rsrctypearticle
creationdate2013
addtitlePLoS ONE
searchscope
0doaj_full
1doaj1
scope
0doaj_full
1doaj1
lsr45$$EView_full_text_in_DOAJ
tmp01Directory of Open Access Journals (DOAJ)
tmp02DOA
startdate20130101
enddate20130101
lsr40PLoS ONE, 01 January 2013, Vol.8 (1), p.e54918
doi10.1371/journal.pone.0054918
citationpf e54918 vol 8 issue 1
lsr30VSR-Enriched:[galeid, pqid, pages]
sort
titleA comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models
authorHao Zhang ; Dror Berel ; Yanping Wang ; Ping Li ; Neil A Bhowmick ; Robert A Figlin ; Hyung L Kim
creationdate20130101
lso0120130101
facets
frbrgroupid3343799588670116274
frbrtype5
newrecords20190714
languageeng
topicSciences (General)
collectionDirectory of Open Access Journals (DOAJ)
prefilterarticles
rsrctypearticles
creatorcontrib
0Hao Zhang
1Dror Berel
2Yanping Wang
3Ping Li
4Neil A Bhowmick
5Robert A Figlin
6Hyung L Kim
jtitlePLoS ONE
creationdate2013
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext_linktorsrc
addata
au
0Hao Zhang
1Dror Berel
2Yanping Wang
3Ping Li
4Neil A Bhowmick
5Robert A Figlin
6Hyung L Kim
atitleA comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models
jtitlePLoS ONE
risdate20130101
volume8
issue1
spagee54918
eissn1932-6203
formatjournal
genrearticle
ristypeJOUR
abstract

Rapamycin analogs, temsirolimus and everolimus, are approved for the treatment of advance renal cell carcinoma (RCC). Currently approved agents inhibit mechanistic target of rapamycin (mTOR) complex 1 (mTORC1). However, the mTOR kinase exists...

pubPublic Library of Science (PLoS)
doi10.1371/journal.pone.0054918
urlhttps://doaj.org/article/0be335298182489f86107f3164770aba
lad01PLoS ONE
oafree_for_read
pagese54918
date2013-01-01